This report was first published by Endpoints News. To see the original version, click here
MoonLake Immunotherapeutics’ only investigational drug showed a clinically meaningful benefit in patients with an aggressive form of inflammatory arthritis, according to Phase 2 data the company shared with Endpoints News on Sunday.
While that news is positive, investors are more focused on whether the product, a nanobody called sonelokimab that blocks IL-17A and F, can gain approval in hidradenitis suppurativa (HS), a painful and disfiguring skin condition.
您已阅读14%（551字），剩余86%（3362字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。